Genomic Health (GHDX) Getting Somewhat Favorable News Coverage, Report Finds
Media headlines about Genomic Health (NASDAQ:GHDX) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Genomic Health earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 44.4363246158034 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- G Bradley Cole Sells 5,000 Shares of Genomic Health, Inc. (GHDX) Stock (americanbankingnews.com)
- Genomic Health (GHDX) Downgraded by Zacks Investment Research (americanbankingnews.com)
- Genomic Health (GHDX) Receives Sell Rating from Barclays (americanbankingnews.com)
- Genomic Health, Inc. (GHDX) Insider Sells $102,406.36 in Stock (americanbankingnews.com)
A number of equities research analysts recently commented on the stock. Zacks Investment Research lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a report on Tuesday. Barclays restated a “sell” rating and set a $28.00 price objective on shares of Genomic Health in a report on Monday. William Blair downgraded shares of Genomic Health from an “outperform” rating to a “market perform” rating in a research report on Wednesday, December 20th. BidaskClub raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Tuesday, December 19th. Finally, ValuEngine raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, December 15th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $31.71.
In other news, insider James J. Vaughn sold 1,379 shares of Genomic Health stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total value of $44,831.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Phillip G. Febbo sold 5,334 shares of Genomic Health stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $36.99, for a total transaction of $197,304.66. The disclosure for this sale can be found here. In the last ninety days, insiders sold 65,717 shares of company stock valued at $2,158,232. 46.20% of the stock is owned by insiders.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.